Bcl-2 and bax expression in advanced non-small cell lung cancer: Lack of correlation with chemotherapy response or survival in patients treated with docetaxel plus vinorelbine

Lung Cancer

Volumn 39, Issue 2, 2003, Pages 139-143

  Krug, Lee M ^a,b   Miller, Vincent A ^a   Filippa, Daniel A ^a   Venkatraman, Ennapadam ^a   Ng, Kenneth K ^a   Kris, Mark G ^a  

^a WEILL CORNELL MEDICAL COLLEGE   (United States)

^b NONE   (United States)

Author keywords

Bax; bcl 2; Docetaxel; Non small cell lung cancer; Vinorelbine

Indexed keywords

DOCETAXEL; NAVELBINE; PROTEIN BAX; PROTEIN BCL 2;

ADVANCED CANCER; ARTICLE; BIOPSY; CANCER SURVIVAL; CHEMOTHERAPY; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; FEASIBILITY STUDY; FISHER EXACT TEST; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; KAPLAN MEIER METHOD; LUNG NON SMALL CELL CANCER; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; STAINING;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BCL-2-ASSOCIATED X PROTEIN; BIOPSY; CARCINOMA, NON-SMALL-CELL LUNG; COHORT STUDIES; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NEOPLASM STAGING; PACLITAXEL; PROGNOSIS; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS C-BCL-2; SURVIVAL RATE; TAXOIDS; TUMOR MARKERS, BIOLOGICAL; VINBLASTINE;

EID: 0037312094     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0169-5002(02)00443-9     Document Type: Article

References (16)

1. Hockenbery D., Nunez G., Milliman C., et al. Bcl-2 is an inner mitochondrial membrane protein that blocks programmed cell death. Nature. 348:1990;334-336.
2. Salgia R., Skarin A.T. Molecular abnormalities in lung cancer. J. Clin. Oncol. 16:1998;1207-1217.
3. Pezzella F., Turley H., Kuzu I., et al. bcl-2 protein in non-small-cell lung carcinoma. N. Engl. J. Med. 329:1993;690-694.
4. Apolinario R.A., van der Valk P., de Jong J.S., et al. Prognostic value of the expression of p53, bcl-2 and bax oncoproteins, and neovascularization in patients with radically resected non-small-cell lung cancer. J. Clin. Oncol. 15:1997;2456-2466.
5. Haldar S., Jena N., Croce C.M. Inactivation of Bcl-2 by phosphorylation. Proc. Natl. Acad. Sci. USA. 92:1995;4507-4511.
6. Haldar S., Basu A., Croce C. Bcl2 is the guardian of microtubule integrity. Cancer Res. 57:1997;229-233.
7. Strobel T., Kraeft S.-K., Chen L.B., Cannistra S.A. BAX expression is associated with enhanced intracellular accumulation of paclitaxel: a novel role for BAX during chemotherapy-induced cell death. Cancer Res. 58:1998;4776-4781.
8. Tai Y.-T., Lee S., Niloff E., et al. BAX protein expression and clinical outcome in epithelial ovarian cancer. J. Clin. Oncol. 16:1998;2583-2590.
9. Aoe K., Kiura K., Ueoka H., et al. Effect of docetaxel with cisplatin or vinorelbine on lung cancer cell lines. Anticancer Res. 19:1999;291-300.
10. Bissery M.C., Vrignaud P., Bayssas M., Lavelle F. Preclinical in vivo activity of docetaxel-containing combinations. Proc. Am. Soc. Clin. Oncol. 14:1995;489.
11. Hino H., Kobayashi K., Hayashihara K., et al. In vitro combination effect of docetaxel (RP56976) with vinca alkaloids on cancer cell lines. Proc. Am. Assoc. Cancer Res. 36:1995;299.
12. Miller V.A., Ng K.K., Krug L.M., et al. Phase I trial of docetaxel and vinorelbine in patients with advanced non-small cell lung cancer. Cancer. 88:2000;1045-1050.
13. Miller V.A., Krug L.M., Ng K.K., et al. Phase II trial of docetaxel and vinorelbine in patients with advanced non-small lung cancer. J. Clin. Oncol. 18:2000;1346-1350.
14. Erlandon R. Ancillary procedures for evaluating human tumors. Diagnostic transmission electron microscopy of tumors, with clinicopathological, immunohistochemical and cytogenetic correlations. 1994;28 Raven, New York.
15. Kaplan E.L., Meier P. Nonparametric estimation from incomplete observations. J. Am. Stat. Assoc. 53:1958;457-481.
16. Ritter J.H., Dresler C.M., Wick M.R. Expression of bcl-2 protein in stage T1N0M0 non-small cell lung carcinoma. Hum. Pathol. 26:1995;1227-1232.